2 Union Square, Union City, CA 94587
contact@NeoBiotechnologies.com
510-376-5603

Home >> Antibodies >> HLA-DRA (MHC II)

HLA-DRA (MHC II)

Mouse Monoclonal Antibody [Clone IPO-10]

Catalog #

Size

20 ug
100 ug
100 ug

Price (USD)

199.00
429.00
429.00

Formulation

Purified Ab with BSA and Azide at 200ug/ml
Purified Ab with BSA and Azide at 200ug/ml
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml

Catalog No

Size

20 ug
100 ug
100 ug

Formulation

Purified Ab with BSA and Azide at 200ug/ml
Purified Ab with BSA and Azide at 200ug/ml
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml

Price (USD)

199.00
429.00
429.00
img

SDS-PAGE Analysis Purified HLA-DRA Mouse Monoclonal Antibody (IPO-10). Confirmation of Integrity and Purity of Antibody.

Product Details

Synonyms

DR alpha chain; HLA class II histocompatibility antigen; HLA class II histocompatibility antigen DR alpha chain; HLA DRA; HLA DRA1; HLA-DRA; HLADRA1; Major histocompatibility complex class II DR alpha; MHC cell surface glycoprotein; MHC class II antigen DRA

Positive Control

Ramos, Daudi or HuT78 cells. Tonsil or lymph node.

Known Applications & Suggested Dilutions

Flow Cyt, IF         More Details

Flow Cytometry (1-2ug/million cells)
Immunofluorescence (1-2ug/ml)
Optimal dilution for a specific application should be determined.

Immunogen

Spleen cells of a patient with hairy cell leukemia (Daudi cells)

Cellular Localization

Cell surface

Species Reactivity

Human. Monkey.

Host / Ig Isotype

Mouse / IgG3, kappa

Mol. Weight of Antigen

~36kDa

Specificity & Comments

MAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The MAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected. '

Related Products



200ug/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Key References

  1. Gluzman D.F. et al., Monoclonal antibodies IPO-3, IPO-4 and IPO-10 against lymphocyte differentiation antigens. Tissue Antigens 33, 151, 1989.
  2. Pinchouk V.G. et al., Monoclonal antibodies IPO-3 and IPO-10 against human B cell differentiation antigens. Anticancer Research 8, 1377-1380, 1988.
  3. Sidorenko S.P. et al., Monoclonal antibodies of IPO series against B cell differentiation antigens in leukemia and lymphoma immunophenotyping. Neoplasma 39, 3-9, 1992.

Bioinformatics

  •  Entrez Gene ID: 3122
  •  Gene Symbol: HLA-DRA
  •  SwissProt: P01903
  •  Chromosome Location: 6p21.3
  •  Unigene: 520048
NBT01090